Figure 1. Mean volume of diagnostic blood drawn on each day from hospital days 1 through 10. Mean blood drawn for laboratory tests on each of the first 10 hospital days, comparing patients who developed moderate to severe hospital-acquired anemia (HAA) with those who did not. The denominator on each hospital day included all patients who remained in the hospital on each respective day hospital day (hospital day 1: 17 676; hospital day 2: 13 632; hospital day 3: 11 403; hospital day 4: 8261; hospital day 5: 5263; hospital day 6: 3339; hospital day 7: 2183; hospital day 8: 1475; hospital day 9: 1060; hospital day 10: 753).
Figure 2. Variation in mean diagnostic blood loss (DBL) across the 57 hospitals included in a contemporary acute myocardial infarction database (Cerner Corp's Hospital Facts database.) Bars represent shrinkage estimates of the mean DBL for patients' entire hospitalizations across each hospital. Black bars represent the mean value for patients with moderate to severe hospital-acquired anemia (HAA), and gray bars present the mean value for patients without moderate to severe HAA. Hospitals are plotted on the x-axis from the hospital with the smallest mean blood loss to the hospital with the largest, ranked separately among those with moderate to severe HAA and without moderate to severe HAA.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Salisbury AC, Reid KJ, Alexander KP, et al. Diagnostic Blood Loss From Phlebotomy and Hospital-Acquired Anemia During Acute Myocardial Infarction. Arch Intern Med. 2011;171(18):1646–1653. doi:10.1001/archinternmed.2011.361
Author Affiliations: Department of Internal Medicine, Division of Cardiovascular Diseases, Saint Luke's Mid America Heart and Vascular Institute, Kansas City, Missouri (Drs Salisbury, Chan, Spertus, and Kosiborod and Ms Reid); University of Missouri–Kansas City School of Medicine, Kansas City (Drs Salisbury, Chan, Spertus, and Kosiborod); Department of Internal Medicine, Division of Cardiovascular Diseases, Duke Clinical Research Institute, Durham, North Carolina (Drs Alexander and Wang); Department of Internal Medicine, Division of Cardiovascular Diseases, University of Colorado–Denver, Aurora (Dr Masoudi); Department of Preventive Medicine, University of Kansas, Kansas City (Dr Lai); and Department of Internal Medicine, Division of Cardiovascular Diseases, Washington University School of Medicine, St Louis, Missouri (Dr Bach).
Background Hospital-acquired anemia (HAA) during acute myocardial infarction (AMI) is associated with higher mortality and worse health status and often develops in the absence of recognized bleeding. The extent to which diagnostic phlebotomy, a modifiable process of care, contributes to HAA is unknown.
Methods We studied 17 676 patients with AMI from 57 US hospitals included in a contemporary AMI database from January 1, 2000, through December 31, 2008, who were not anemic at admission but developed moderate to severe HAA (in which the hemoglobin level declined from normal to <11 g/dL), a degree of HAA that has been shown to be prognostically important. Patients' total diagnostic blood loss was calculated by multiplying the number and types of blood tubes drawn by the standard volume for each tube type. Hierarchical modified Poisson regression was used to test the association between phlebotomy and moderate to severe HAA, after adjusting for site and potential confounders.
Results Moderate to severe HAA developed in 3551 patients (20%). The mean (SD) phlebotomy volume was higher in patients with HAA (173.8 [139.3] mL) vs those without HAA (83.5 [52.0 mL]; P < .001). There was significant variation in the mean diagnostic blood loss across hospitals (moderate to severe HAA: range, 119.1-246.0 mL; mild HAA or no HAA: 53.0-110.1 mL). For every 50 mL of blood drawn, the risk of moderate to severe HAA increased by 18% (relative risk [RR], 1.18; 95% confidence interval [CI], 1.13-1.22), which was only modestly attenuated after multivariable adjustment (RR, 1.15; 95% CI, 1.12-1.18).
Conclusions Blood loss from greater use of phlebotomy is independently associated with the development of HAA. These findings suggest that HAA may be preventable by implementing strategies to limit blood loss from laboratory testing.
Both chronic anemia, present at the time of admission to the hospital, and hospital-acquired anemia (HAA), which develops during hospitalization in patients with a normal hemoglobin level at admission, are associated with greater mortality and worse health status in patients with acute myocardial infarction (AMI).1-5 However, in contrast to chronic anemia, HAA could potentially be prevented by implementing strategies to reduce blood loss in high-risk patients. Although in-hospital bleeding is a risk factor for HAA and is already recognized as an important target for quality improvement, HAA seems to be multifactorial and commonly develops in the absence of bleeding.4,6
Several factors other than bleeding might be associated with HAA, including blunted hematopoetic response and phlebotomy. Impaired hematopoesis, resulting from preexisting and nonmodifiable factors, such as inflammation, chronic renal disease, or congestive heart failure, could impair recovery from even minor blood loss during hospitalization.7,8 It is important to note that blood loss from diagnostic phlebotomy has been linked to in-hospital declines in hemoglobin level and requirement for blood transfusion in other patient populations and may be a risk factor for HAA in patients hospitalized with AMI.9-11 Furthermore, blood loss from phlebotomy could be an actionable target for intervention. Limiting scheduled phlebotomy, use of pediatric blood tubes, and more frequent use of stored serum specimens in high-risk patients may all minimize diagnostic blood loss (DBL)12-14 and could reduce the incidence and severity of HAA.
To our knowledge, the relationship between diagnostic phlebotomy and the risk of HAA has not been previously explored in patients with AMI. Accordingly, we used Cerner Corp's (Kansas City, Missouri) Health Facts, an electronic medical record database, to evaluate the association between DBL and HAA in an unselected cohort of patients with AMI hospitalized in 57 medical centers. Health Facts provided an ideal opportunity to address this hypothesis since the database contains detailed information on the frequency and type of laboratory testing, as well as patients' hemoglobin levels, across diverse group of US hospitals.
To identify the association between phlebotomy and HAA, we used the Cerner Corp's Health Facts database (see the “Methods” section of the eAppendix).15,16 The database captured deidentified data from the Cerner electronic medical record for patients admitted to participating hospitals from January 1, 2000, through December 31, 2008. Data included hospital characteristics; patients' demographic characteristics, medical history, and comorbidities (using the International Classification of Diseases, Ninth Revision, Clinical Modification [ICM-9-CM ] codes); laboratory studies (venous and arterial blood draws and time of phlebotomy); medications; procedures; and complications. All data were deidentified before they were provided to the investigators, and an exemption from review was provided by the Saint Luke's Hospital (Kansas City, Missouri) institutional review board.
We defined anemia using age-, sex-, and race-specific criteria described by Beutler and Waalen17 as a hemoglobin level lower than 13.7 g/dL for white men aged 20 to 59 years, lower than 13.2 g/dL for white men 60 years or older, lower than 12.9 g/dL for black men aged 20 to 59 years, lower than 12.7 g/dL for black men 60 years or older, lower than 12.2 g/dL for white women, and lower than 11.5 g/dL for black women. (To convert hemoglobin to grams per liter, multiply by 10.0.) This classification is based on large, contemporary cohorts and identifies anemia more accurately than the World Health Organization (WHO) definition.17,18 In the absence of race-specific data for patients of other racial backgrounds (<5% of patients), we applied diagnostic criteria for white patients. Patients were classified as having HAA if their initial hemoglobin level was higher than the diagnostic thresholds but their lowest (nadir) hemoglobin level during hospitalization fell below the diagnostic threshold for anemia. Consistent with prior work, HAA was classified as mild if the nadir hemoglobin level was 11.0 g/dL or greater and moderate to severe if the nadir hemoglobin level was lower than 11.0 g/dL.4 The outcome for this study was the development of moderate to severe HAA, since only moderate to severe HAA has been shown to be prognostically important.4
We included all patients hospitalized with a primary discharge diagnosis of AMI as determined by ICM-9-CM diagnostic codes 410.xx, and further confirmed AMI by requiring that patients had at least 1 elevated cardiac biomarker (troponin or creatine kinase MB) and were not discharged within the first 24 hours. The inclusion and exclusion criteria are listed in detail in the eAppendix and eFigure 1; key exclusions were patients who underwent coronary bypass grafting during hospitalization (etiology and outcomes of anemia are different in these patients) and those already anemic at admission to the hospital.4 The analytic cohort included 17 676 patients with AMI and no anemia on admission from 57 hospitals.
The date and time of every phlebotomy event, and results from the laboratory tests collected with each blood draw, were included in Health Facts. We identified the number and types of blood tubes that would be needed to run the laboratory tests recorded in the medical record. Several conservative assumptions were made when calculating phlebotomy volumes. With each blood draw, all laboratory tests that could be processed from a particular type of blood tube were assumed to have been run from a single tube. We further assumed that with each blood draw, only the minimal blood volume needed to run the required tests was drawn and that no blood was wasted at the time of blood draws. Hematology tubes were assigned a volume of 5 mL; coagulation laboratory tubes, 4.5 mL; chemistry/miscellaneous laboratory tubes, 5 mL; arterial blood gas tubes, 2 mL; and blood cultures, 10 mL, based on estimates from prior literature.11 For each patient, these blood volumes were multiplied by the number of blood tubes of each type collected during their hospitalization to arrive at the total blood volume drawn for diagnostic tests during the entire hospitalization. We also calculated the mean blood volume drawn per 24 hours of hospitalization. Finally, we calculated the mean phlebotomy volumes on each of days 1 to 10 of hospitalization. For example, we calculated the mean blood volume drawn on hospital day 1 among the entire cohort, whereas only patients who remained hospitalized 5 days after admission were included in the calculation of mean phlebotomy volumes drawn on hospital day 5.
Baseline patient characteristics, laboratory values, in-hospital treatments, and complications of patients who developed moderate to severe HAA were compared with those who did not. For descriptive purposes, we presented categorical data as frequencies and compared groups using χ2 tests. Continuous variables were reported as means (SDs), and differences were compared using t tests. We used the Wilcoxon rank-sum test to compare length of stay owing to its skewed distribution, and results are reported as the median [interquartile range].
When comparing DBL across hospitals in the Health Facts database, we generated shrinkage estimates to account for lower enrollment from small hospitals. This approach pulls estimates from smaller hospitals toward the overall mean. Estimates were generated using a generalized linear model, regressing site as a random effect on diagnostic blood volume as the dependent variable.
We used hierarchical multivariable Poisson regression with robust error variance, with hospital as a random variable, to account for clustering within hospitals.19 To identify the independent association between phlebotomy volume and development of moderate to severe HAA, we adjusted for variables that were identified a priori based on clinical experience and prior literature. These included demographics (age, sex, race [white vs other]), clinical characteristics (chronic kidney disease, heart failure, hypertension, diabetes mellitus, prior myocardial infarction [MI]) and MI type and treatments (ST-elevation MI vs non–ST-elevation MI; thrombolytic drugs; in-hospital cardiac catheterization or percutaneous coronary intervention; use of aspirin, thienopyridines, glycoprotein IIb/IIIa inhibitors, heparin, and bivalirudin), and in-hospital complications (acute renal failure, mechanical ventilation, and cardiogenic shock).
Missing data for model covariates were minimal. The initial creatinine level was the variable that was most often missing (in 247 patients [1.4%]). These data were assumed to be missing at random and were imputed using sequential regression imputation with IVEware software (Survey Methodology Program, Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor).20
We pursued several sensitivity analyses to confirm the robustness of our findings and to further investigate the time course of moderate to severe HAA development (eAppendix). First, to understand when patients developed moderate to severe HAA, we calculated the proportion of patients who developed new moderate to severe HAA on each of the first 10 hospital days. Second, we tested an interaction between length of stay and DBL and repeated our analyses after stratifying by length of stay. We then repeated our analyses after excluding patients with known bleeding events and after using the WHO anemia definition.18 Finally, we repeated the analyses using several alternative assumptions for standard adult blood tube volumes and using volumes reported to fill pediatric blood tubes.9,11,13,21,22 All statistical analyses were evaluated at a 2-sided significance level of P = .05 and performed using SAS (version 9.2; SAS Institute Inc, Cary, North Carolina) and R (version 2.0; Vienna, Austria) software.
One of every 5 patients with AMI developed moderate to severe HAA (3551 patients [20.1%]). The baseline characteristics of patients who did and did not develop moderate to severe HAA are compared in Table 1. The mean (SD) hemoglobin values declined during hospitalization in both groups, with greater declines in those with moderate to severe HAA compared with those without moderate to severe HAA (3.9 [1.6] g/dL vs 1.6 [1.1] g/dL; P < .001).
The mean, median, and range of DBL during the entire hospitalization and per 24 hours in the hospital are presented in Table 2, as well as the phlebotomy volume per type of blood tube drawn. The estimated mean (SD) blood loss from phlebotomy was nearly 100 mL higher over the course of hospitalization among patients who developed moderate to severe HAA compared with those who did not (173.8 [139.3] mL vs 83.5 [52.0] mL; P < .001); the mean (SD) blood loss per 24 hours of hospitalization was modestly higher with greater variability in those with moderate to severe HAA compared with those without moderate to severe HAA (24.4 [34.1] mL vs 22.8 [20.9] mL; P < .001). Particularly large DBL over the entire hospitalization was relatively common in patients who developed moderate to severe HAA (>300 mL: 444 patients [12.5%]; >500 mL: 136 patients [3.8%]) and was infrequent in patients who did not develop moderate to severe HAA (>300 mL: 117 patients [0.8%]; >500 mL: 12 patients [0.08%]). When DBL was estimated for each hospital day, the mean DBL was highest on the first 2 hospital days and declined subsequently (Figure 1).
There was significant variably in the average volume of blood drawn for laboratory testing across Health Facts hospitals. Shrinkage estimates of mean DBL for the entire cohort ranged from 53.0 mL (95% confidence interval [CI], 47.7-58.3 mL) to 109.6 mL (95% CI, 104.5-114.6 mL). There was even greater hospital variability among patients with moderate to severe HAA (Figure 2) (119.1 mL [95% CI, 92.1-146.1 mL] to 246.0 mL [95% CI, 219.2- 272.7 mL]). There was a significant association between greater incidence of moderate to severe HAA at a hospital and higher mean DBL (P < .001; eFigure 2).
The volume of diagnostic blood drawn was associated with moderate to severe HAA. In unadjusted analyses, each 50 mL of blood drawn was associated with an 18% increase in risk of moderate to severe HAA (relative risk [RR], 1.17; 95% CI, 1.14-1.21; P < .001). After adjusting for site and potential confounders, the relationship between greater DBL and higher risk of moderate to severe HAA persisted (per 50 mL: RR, 1.15; 95% CI, 1.12-1.18; P < .001; eTable 1).
The risk of moderate to severe HAA was highest on the first hospital day (10.5%), followed by a daily risk ranging between 2.8% and 4.5% on hospital days 2 through 10 (eFigure 3). The results of sensitivity analyses, including stratifying by length of stay, excluding patients with known bleeding, using the WHO anemia definition and calculating DBL with alternative tube volumes (Table 3), were all consistent with the primary analysis (see the “Results” section of the eAppendix).
Hypothetically, if low-volume pediatric blood tubes were used in place of standard tubes for all blood draws, the mean (SD) estimated DBL volume in the overall cohort could decline dramatically to 35.5 (39.0); for moderate to severe HAA, it would decline to 65.3 (62.2) mL; and for mild HAA or no HAA, it would decline to 28.0 (25.5) mL.
To our knowledge, our study is the first to directly assess the association between DBL and HAA in a large, unselected cohort of patients with AMI from hospitals across the United States. Diagnostic blood loss was substantial, particularly among individuals with HAA, and varied widely across hospitals, suggesting that process-of-care differences may influence DBL. It is important to note that DBL was independently associated with a higher risk of HAA and that this association remained robust after multivariable adjustment and in several sensitivity analyses.
Prior studies have shown that HAA is common and associated with higher mortality and worse health status after AMI.4,6,24 In our study, 1 in 5 patients who did not have baseline anemia (and did not undergo coronary bypass surgery) developed moderate to severe HAA. Several factors contribute to development of HAA. Some of these are not modifiable (age, sex, chronic kidney disease, acute inflammation from AMI),4,25 but 2 are clearly under the control of health care providers: prevention of periprocedural bleeding and minimization of phlebotomy. Alternative anticoagulants such as bivalirudin, closure devices, and radial access for coronary angiography all reduce the incidence of periprocedural bleeding.26-29 However, no clear bleeding event is identified in many patients with HAA.4,6 Although phlebotomy has been suggested as a cause of in-hospital hemoglobin level declines in patients with AMI,30 to our knowledge, our study is the first to identify DBL as an independent predictor of HAA in a contemporary cohort reflecting real-world patient care and highlights phlebotomy as a potentially modifiable risk factor.
Our findings have important clinical implications. Among patients who developed HAA, the mean estimated phlebotomy volume was 173.8 mL, which is equivalent to nearly half a unit of whole blood, and over 12% had more than 300 mL of blood drawn over the course of hospitalization. Diagnostic blood loss remained relatively constant throughout the course of hospital stay after the first 2 days of hospitalization and was particularly high among patients with long lengths of stay. Since most diagnostic evaluation and therapeutic interventions often occur early during AMI hospitalization, it is likely that much of the blood taken later during hospitalization represents routine, scheduled laboratory draws that could lead to ongoing blood loss. Our findings are likely generalizable to other populations of seriously ill medical patients. In this regard, further studies that establish whether minimizing DBL can prevent HAA and improve patient outcomes could have broad implications for hospitalized patients.
Our findings also indicate that reduction of blood loss from phlebotomy could be important to limit development and severity of HAA.12-14 For example, we found that estimates of phlebotomy volumes were dramatically lower with pediatric tubes, highlighting a promising intervention to limit DBL. It might be possible to reduce DBL with no additional cost to hospitals (using pediatric tubes or stored serum samples) or even potential cost savings (reducing unnecessary, scheduled blood draws). Although the universal use of pediatric tubes may not be possible at some hospitals where smaller tubes are not compatible with analytic equipment, a potential alternative in these cases may be to fill standard adult tubes with less blood. For example, Xu et al31 reported similar diagnostic accuracy for automated hematology testing when filling standard 4-mL tubes with only 1 or 2 mL of blood. Nevertheless, while DBL may be a key factor in HAA development, is likely not the only contributor. Future HAA prevention efforts are most likely to be effective if they incorporate multimodal interventions that both minimize unnecessary DBL and prevent bleeding.
Several limitations of our study should be considered. First, calculation of phlebotomy volume relied on estimates of the amount of blood required for each tube. We included several conservative assumptions, such as assuming that only 1 tube of each type was drawn with each phlebotomy event, and not including an estimate of wasted blood to avoid overestimating DBL. Accordingly, estimates presented in this article likely represent the minimum amount of DBL that could have occurred. Moreover, we conducted sensitivity analyses in which we used alternative volumes for the amount of blood required for each tube and found that DBL was substantial regardless of which estimates were used. Second, we were unable to assess the impact of hemodilution from intravenous fluids or fluid retention; however, since large hemoglobin level declines were required to develop HAA, hemodilution is an unlikely culprit for HAA in our patient population. Third, hemoglobin assessments were not performed at regular intervals because the Health Facts database reflects routine clinical practice. Although there was variability in the number and timing of hemoglobin assessments, these data are generalizable to real-world clinical practices in which these tests are obtained at the discretion of the treating physician. Fourth, we used a single threshold for moderate to severe HAA of hemoglobin levels lower than 11 g/dL. Using this threshold, an African American woman required a smaller (>0.5 g/dL) hemoglobin decline to be classified as having HAA. Ideally, age-, sex-, and race-specific thresholds would be used to define moderate to severe HAA; however, there are no reports in the literature that describe different thresholds for anemia severity by sex, race, or age. Moreover, regardless of race, a prior study (using the same definition of anemia as the present study) demonstrated that hemoglobin level declines from normal levels to less than 11 g/dL are associated with greater long-term mortality.4 In addition, using the WHO anemia definition18 (which is not race specific) did not change our results. Finally, patients with HAA had greater disease severity and more comorbidities than patients who did not, as indicated by their demographics, comorbidities, and in-hospital complications. Given the retrospective nature of these analyses, residual and unmeasured confounding cannot be excluded, and no causal inference can be drawn from these observational data. Randomized trials are needed to test the hypothesis that reducing phlebotomy prevents HAA and improves patients' outcomes.
In conclusion, blood loss from phlebotomy is substantial in patients with AMI, varies across hospitals, and is independently associated with the development of HAA. Studies are needed to test whether strategies that limit both the number of blood draws and the volume of blood removed for diagnostic testing can prevent HAA and improve clinical outcomes in patients with AMI.
Correspondence: Mikhail Kosiborod, MD, Internal Medicine, Division of Cardiovascular Disease, Saint Luke's Mid America Heart and Vascular Institute, 4401 Wornall Rd, Kansas City, MO 64111 (email@example.com).
Accepted for Publication: April 26, 2011.
Published Online: August 8, 2011. doi:10.1001/archinternmed.2011.361
Author Contributions: Drs Salisbury and Kosiboro had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Salisbury, Lai, and Kosiborod. Acquisition of data: Reid, Bach, and Kosiborod. Analysis and interpretation of data: Salisbury, Reid, Alexander, Masoudi, Lai, Chan, Bach, Wang, Spertus, and Kosiborod. Drafting of the manuscript: Salisbury, Reid, Wang, and Kosiborod. Critical revision of the manuscript for important intellectual content: Salisbury, Reid, Alexander, Masoudi, Lai, Chan, Bach, Spertus, and Kosiborod. Statistical analysis: Salisbury, Reid, Lai, and Kosiborod. Obtained funding: Spertus and Kosiborod. Administrative, technical, and material support: Wang, Spertus, and Kosiborod. Study supervision: Lai and Kosiborod.
Financial Disclosure: Dr Masoudi is on an advisory board for Amgen and has performed blinded end-point adjudication for Axio Research. Dr Bach has received research grants from AstraZeneca, Schering-Plough Corp, Merck & Co Inc, Bristol-Myers Squibb, The Medicines Co, and Eli Lilly and Co and has been a consultant (on a clinical events committee) for Roche Diagnostics, Eli Lilly and Co, Forest Laboratories, and Wyeth/Pfizer. Dr Wang has received research grants from Bristol-Myers Squibb/Sanofi, Daichi Sankyo, Canyon Pharmaceuticals, Eli Lilly and Co, Sanofi-Aventis, Schering Plough, Merck & Co Inc, and The Medicines Co and has been a consultant for Medco and AstraZeneca. Dr Spertus has received research grants from the National Heart, Lung, and Blood Institute, the American Heart Association Pharmaceutical Round Table (AHA-PRT), the American College of Cardiology Foundation Task Force, Johnson and Johnson, Amgen, Eli Lilly and Co, Evaheart Medical USA Inc, and Sanofi-Aventis; has received other research support from Roche Diagnostics and Atherotech Diagnostics Lab; and has been a consultant and/or member of an advisory board for St Jude Medical Inc, United Healthcare, and Novartis Pharmaceuticals Corp. Dr Kosiborod has been a consultant for Sanofi-Aventis and Boehringer-Ingelheim.
Funding/Support: Drs Salisbury, Spertus, and Kosiborod are funded in part by an award from the AHA-PRT and David and Stevie Spina.
Role of the Sponsors: The AHA had no role in the design, conduct, data collection, management, analysis, or interpretation of data, and had no role in preparation, review, or approval of the manuscript. The Cerner Corp facilitated collection and deidentification of the data but had no role in the funding of the study, design, conduct, management, analysis, or interpretation of the data, and had no role in preparation, review, or approval of the manuscript.
Create a personal account or sign in to: